Company Encyclopedia
View More
name
Yifan Pharmaceutical
002019.SZ
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 and original B5. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd.
3.157 T
002019.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking96/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.70%C
    • Profit Margin7.80%B
    • Gross Margin46.92%B
  • Growth ScoreB
    • Revenue YoY4.57%C
    • Net Profit YoY222.87%A
    • Total Assets YoY5.95%B
    • Net Assets YoY3.43%C
  • Cash ScoreB
    • Cash Flow Margin1282.44%B
    • OCF YoY4.57%C
  • Operating ScoreC
    • Turnover0.41C
  • Debt ScoreB
    • Gearing Ratio33.55%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Yifan Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 388 million yuan, an increase of 5.84%

    According to the Zhitong Finance APP, Yifan Pharmaceutical released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.923 billion yuan, a year-on-year increase of 1.67%. The net profit attributable to shareholders of the listed company was 388 million yuan, a year-on-year increase of 5.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 315 million yuan, a year-on-year increase of 25.17%. The basic earnings per share were 0.32 yuan

    Zhitong·
    SZ
    002019
    -1.33%
    Zhitong·
    SZ
    002019
    -1.33%

    On the morning of the first session of the 2025 National Negotiation, 6 pharmaceutical companies have completed negotiations and exited, involving products including analgesics and anti-infectives

    The national medical insurance catalog on-site negotiations for 2025 were held on October 30, with 6 pharmaceutical companies completing the negotiations and leaving, involving analgesics and anti-infection drugs. Participating companies include Haisco, Yifan Pharmaceutical, Astrazeneca, CSPC PHARMA, and LUYE PHARMA. Astrazeneca Vice President Huang Bin left the negotiations with a smile

    Zhitong·
    US
    AZN
    -0.90%
    HK
    01093
    +0.78%
    HK
    02186
    -0.99%
    Zhitong·
    US
    AZN
    -0.90%
    HK
    01093
    +0.78%
    HK
    02186
    -0.99%

    Yifan Pharmaceutical: The drug registration application for Sodium Salbutamol Powder has been accepted

    Yifan Pharmaceutical announced that the drug registration application for its wholly-owned subsidiary Sichuan Defeng Pharmaceutical Co., Ltd.'s sodium sapropterin dihydrochloride granules has been accepted by the National Medical Products Administration. This drug is suitable for reducing blood phenylalanine levels in patients with tetrahydrobiopterin-responsive phenylketonuria, applicable to adults and children over 1 month old. The application was submitted in September 2025 and has been accepted

    Zhitong·
    SZ
    002019
    -1.33%
    Zhitong·
    SZ
    002019
    -1.33%

    Yifan Pharmaceutical Subsidiary Gets Regulatory Approval for Antifungal Drug

    (MT Newswires) -- Yifan Pharmaceutical (SHE:002019) subsidiary Hefei Yifan Biological Pharmaceutical obtained drug registration from China's medical products administrator for isavuconazole sulfate for injection. The broad-spectrum antifungal drug is used to treat infections such as aspergillosis and mucormycosis in adults, according to a filing with the Shanghai bourse. The validity is until September 2030. Shares of the pharmaceutical company were down 1% in recent trade.

    marketscreener·
    SZ
    002019
    -1.33%
    marketscreener·
    SZ
    002019
    -1.33%

    Yifan Pharmaceutical obtained a drug registration certificate

    According to the Zhitong Finance APP, Yifan Pharmaceutical announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the Drug Registration Certificate for injectable isavuconazole issued by the National Medical Products Administration on September 15, 2025. Injectable isavuconazole is an anti-infective drug indicated for the treatment of the following infections in adult patients: invasive aspergillosis and invasive mucormycosis

    Zhitong·
    SZ
    002019
    -1.33%
    Zhitong·
    SZ
    002019
    -1.33%
    © 2025 Longbridge｜Disclaimer